Almitan Tablet
Almotriptan
6.5 mg
Opsonin Pharma Limited
| Pack size | 4's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 25.00 AED |
Indications
Almitan Tablet is used for:
Migraine headache, Acute migraine attacks
Adult Dose
Oral
Acute migraine attacks
Adult: Initially, 6.25-12.5 mg. May repeat 2 hr later if needed. Max: 2 doses/24 hr.
Child Dose
Oral
Child: Migraine
Indicated for acute treatment of migraine headache pain in adolescents with a history of migraine attacks with or without aura usually lasting >4 hr (when untreated)
<12 years: Safety and efficacy not established
>12 years: 6.25-12.5 mg PO at onset of headache; may repeat once after 2 hr
Not to exceed 25 mg/day
Renal Dose
Renal Impairment Initially, 6.25 mg as a single dose.
Max: 12.5 mg/24 hr.
Administration
May be taken with or without food.
Contra Indications
Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm.
Uncontrolled hypertension. Severe hepatic or renal impairment.
Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache.
Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative;
Concurrent use or within 2 wk of discontinuing an MAOI.
Precautions
Serious adverse cardiac events, including acute myocardial infarction and life-threatening disturbances of cardiac rhythm
It is strongly recommended that Almotriptan not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors. In very rare cases, serious cardiovascular events have been reported in association with Almotriptan use in the absence of known cardiovascular disease. If Almotriptan is considered, patients should first have a cardiovascular evaluation. If the evaluation is satisfactory, first dose should take place in a physician’s office setting
Sensations of pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw: generally not associated with myocardial ischemia, but patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD
Cerebrovascular events, some fatal
Gastrointestinal ischemic events and peripheral vasospastic reactions (e.g., Raynaud’s syndrome)
Potentially life-threatening serotonin syndrome, particularly in combination with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Monitor patients for neurologic changes and gastrointestinal symptoms if concomitant treatment is clinically warranted
Medication overuse headache: Detoxification may be necessary
Increase in blood pressure, very rarely associated with significant clinical events
Use with caution in patients with a known hypersensitivity to sulfonamides
Pregnancy-Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
Interactions
Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors.
Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.
Contraindicated (15)
bromocriptine
cabergoline
dihydroergotamine
dihydroergotamine intranasal
eletriptan
ergoloid mesylates
ergotamine
frovatriptan
methylergonovine
naratriptan
procarbazine
rizatriptan
sumatriptan
sumatriptan intranasal
zolmitriptan
Serious - Use Alternative (35)
carbamazepine
citalopram
clarithromycin
cyclobenzaprine
desvenlafaxine
dolasetron
erythromycin base
erythromycin ethylsuccinate
erythromycin lactobionate
erythromycin stearate
fluvoxamine
granisetron
isocarboxazid
itraconazole
ketoconazole
levoketoconazole
linezolid
lorcaserin
methylene blue
nefazodone
netupitant/palonosetron
ondansetron
ozanimod
palonosetron
phenelzine
procarbazine
rasagiline
rifabutin
rifampin
saquinavir
St John's Wort
tedizolid
tranylcypromine
vilazodone
vortioxetine
Adverse Effects
Side effects of Almotriptan :
1-10%
Somnolence (1-5%),Dizziness (3-4%),Nausea (1-3%),Vomiting (2%),Dry mouth (1-2%),Headache (1-2%),Nausea (1-2%),Paresthesia (1-2%),Paresthesia (1%),Somnolence (>1%)
<1%
Infrequent (0.01-0.001%)
Anxiety, asthenia, chills, CNS stimulation, fatigue, hypesthesia, tremor, Pruitus, rash, Diaphoresis, dysmenorrhea, hyperglycemia, increased thirst, Abdominal cramp, gastroenteritis
Back pain, myalgia, neck pain, rigid neck, Increased CPK, Bronchitis, chest pain, dyspnea, pharyngitis, rhinitis, sinusitis, Conjunctivitis, tinnitis, vertigo
Potentially Fatal: Serious cardiac events.
Mechanism of Action
Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.
Note
Almitan 6.5 mg Tablet manufactured by Opsonin Pharma Limited. Its generic name is Almotriptan. Almitan is availble in Bangladesh.
Farmaco BD drug index information on Almitan Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.